Skip to main content

In 2011, Valiant took over Edmonton-based Afexa Life Sciences Inc., acquiring the well-known flu treatment Cold-FX

Kevin Van Paassen/The Globe and Mail

Valeant Pharmaceuticals International Inc. posted a 43-per-cent rise in fourth-quarter revenue but booked a net loss due to acquisition-related costs.

Canada's largest publicly traded drug company, Valeant said total revenue in the fourth quarter reached $986-million (U.S.), compared with $688-million in the year-earlier period.

The global leader in dermatology products saw a net loss of $89-million or 29 cents per share in the fourth quarter, compared with a profit of $55.85-million or 18 cents.

Story continues below advertisement

Restructuring, acquisition-related and other costs in the quarter came to $261.8-million, up from $56.7-million.

Montreal-based Valeant made more than a dozen acquisitions last year, including the $2.6-billion takeover of Medicis Pharmaceutical Corp. of Scottsdale, Ariz., a maker of skin-care products.

On a cash-EPS basis, fourth-quarter adjusted income was $380-million or $1.22 per share, an increase of 30 per cent over the fourth quarter of 2011, the company said Thursday.

Valeant was previously known as Biovail Corp., the pharmaceutical company once controlled by Ottawa Senators owner Eugene Melnyk. California-based Valeant and Biovail merged in 2010 and the new entity shifted its focus to therapeutic and aesthetic products, notably oral acne medication Solodyn and anti-wrinkle injection Dysport.

Among earlier deals, Valiant took over Edmonton-based Afexa Life Sciences Inc. in 2011 for about $88-million, acquiring the well-known flu treatment Cold-FX.

Valeant also has products in the neurological and branded-generic drug categories.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter